Over the past two decades, HIV research has entered an era of unprecedented technological sophistication, marked by advances in gene therapy, immuno-engineered cells, nanomedicine, and precision vaccines. Yet, I argue that scientific feasibility alone does not guarantee clinical impact. The translation of cutting-edge biotherapies into real-world benefit is constrained by ethical, logistical, economic, and geopolitical barriers—particularly in regions most affected by HIV. In this article, I critically examine the translational bottlenecks, bioethical dilemmas, and global equity challenges associated with next-generation anti-HIV biotherapies. I conclude that the ultimate success of HIV cure strategies will depend not only on biological efficacy, but on ethical legitimacy, societal trust, and deliberately engineered accessibility. Keywords : HIV cure,Global health equity,Bioethics,Translational research,Health justice,Biotherapy deployment,Manufacturing scalability,Regulatory frameworks, Access to medicines,Health systems strengthening,Gene therapy,Cell therapy,Low- and middle-income countries (LMICs), Community engagement,Health policy